IL2 and type 1 diabetes mellitus: When prepared as IL-2-Fc fusion proteins to increase half-life, these IL-2 muteins were superior to wild-type IL-2-Fc in the treatment of type I diabetes (T1D) in a pre-clinical mouse model (56).